{"id":203228,"name":"AMGEN USA INC.","slug":"amgen-usa-inc","state":"DC","description":"Biotechnology company.","totalSpending":1200000,"filings":20,"yearlySpending":[{"year":2019,"income":180000},{"year":2020,"income":180000},{"year":2021,"income":180000},{"year":2022,"income":180000},{"year":2024,"income":240000},{"year":2025,"income":240000}],"firms":["MARSHALL & POPP, LLC"],"lobbyists":["HAZEN MARSHALL","MONICA POPP"],"issues":["PHA","CPT","TRD","MMM","BUD"],"sampleDescriptions":["Prescription drug value issues.\nBiosimilars.\n340B issues.","Prescription drug value issues.\n\nBiosimilars.\n\n340B issues.\n\nPatents and protection of intellectual property issues.","Issues related to prescription drug value. \n\nS.2543: Prescription Drug Pricing Reduction Act of 2019.\n\nH.R.3: Lower Drug Costs Now Act of 2019.\n\nH.R.19: Lower Costs, More Cures Act of 2019.\n\nBiosimilars.\n\n340B issues.\n\nPatents and protection of intellectual property issues.","Issues related to prescription drug value. \n\nS.2543: Prescription Drug Pricing Reduction Act of 2019.\n\nH.R.3: Lower Drug Costs Now Act of 2019.\n\nH.R.19/S.3129: Lower Costs, More Cures Act of 2019.\n\nBiosimilars.\n\n340B issues.\n\nPatents and protection of intellectual property issues.\n\nIssues related to the COVID-19 pandemic.\n\nH.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020.\n\nH.R.6201: Families First Coronavirus Response Act.\n\nH.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.","Issues related to prescription drug value. \n\nIssues related to supply chain and Buy America requirements.\nS.2543: Prescription Drug Pricing Reduction Act of 2019.\n\nH.R.3: Lower Drug Costs Now Act of 2019.\n\nH.R.19/S.3129: Lower Costs, More Cures Act of 2019.\n\nBiosimilars.\n\n340B issues.\n\nPatents and protection of intellectual property issues.\n\nIssues related to the COVID-19 pandemic, including patient access of Part B drugs.\n\nH.R.6800: The Heroes Act.","Issues related to prescription drug value. \n\nIssues related to supply chain and Buy America requirements.\n\nS.2543: Prescription Drug Pricing Reduction Act of 2019.\n\nH.R.3: Lower Drug Costs Now Act of 2019.\n\nH.R.19/S.3129: Lower Costs, More Cures Act of 2019.\n\nBiosimilars.\n\n340B issues.\n\nPatents and protection of intellectual property issues.\n\nIssues related to the COVID-19 pandemic, including patient access of Part B drugs.\n\nH.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act.\n\nS.4775: Delivering Immediate Relief to America's Families, Schools and Small Businesses Act.\n\nH.R.113 [116th]: Consolidated Appropriations Act, 2021.\n\nIssues related to the end stage renal disease (ESRD) prospective payment system (PPS) proposed rule.\n\nS.551: REFUND Act of 2019, issues related to vial size.","Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act and S.1260, the United States Innovation and Competition Act.","Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).","Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.\n\nIssues related to the CY 2022 ESRD PPS Proposed Rule.","Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.","Issues related to the False Claims Act, including amendments to H.R.3684 - Infrastructure Investment and Jobs Act.","Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.","Issues related to the False Claims Act, including S.2428 - False Claims Amendments Act of 2021.","Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.","Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act and H.R.4521/S.1260, the United States Innovation and Competition Act.","Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes. H.R.6833 - Making continuing appropriations for fiscal year 2023.","Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act, H.R.4521/S.1260, the United States Innovation and Competition Act, and H.R. 4346, the CHIPS and Science Act.","Issues related to prescription drug value, including implementation of H.R.5376, the Inflation Reduction Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833 - Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.","Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act.","Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act, and H.R. 4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. S.Res. 496 and S.Res.566 - National Cholesterol Education Month. S. 3558, Biosecure."],"years":[2019,2020,2021,2022,2024,2025]}